Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

• Main Authors: Luisa Chocarro de Erauso (Author), Miren Zuazo (Author), Hugo Arasanz (Author), Ana Bocanegra (Author), Carlos Hernandez (Author), Gonzalo Fernandez (Author), Maria Jesus Garcia-Granda (Author), Ester Blanco (Author), Ruth Vera (Author), Grazyna Kochan (Author), David Escors (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2020-04-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Cancer immunotherapies targeting immune checkpoints such as programmed cell-death protein 1 (PD-1) and its ligand programmed cell-death 1 ligand 1 (PD-L1), are revolutionizing cancer treatment and transforming the practice of medical oncology. However, despite all the recent successes of this type o...